Indication: Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson’s disease.
Pharmacology: Pergolide is an ergot derivative dopamine receptor agonist at both D1 and D2 receptor sites. Pergolide is 10 to 1,000 times more potent than bromocriptine on a milligram per milligram basis in various in vitro and in vivo test systems. Pergolide mesylate inhibits the secretion of prolactin in humans; it causes a transient rise in serum concentrations of growth hormone and a decrease in serum concentrations of luteinizing hormone. In Parkinson’s disease, pergolide mesylate is believed to exert its therapeutic effect by directly stimulating postsynaptic dopamine receptors in the nigrostriatal system.
Mechanism Of Action: Pergolide is a potent dopamine receptor agonist. It directly stimulates post-synaptic dopamine receptors at both D1 and D2 receptor sites in the nigrostriatal system.
Drug Category: Neuroprotective Agents; Antiparkinson Agents; Antidyskinetics; Dopamine Agonists; Central Nervous System Agents; ATC:N04BC02
Absorption: Significant amount may be absorbed (evidence on bioavailability still lacking).
Interactions:
DrugBank: Interactions for Pergolide
Interactions for Pergolide:
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide,
ordinarily should not be administered concurrently with Permax (a dopamine agonist); these agents may diminish the
effectiveness of Permax. Because pergolide mesylate is approximately 90% bound to plasma proteins, caution should be
exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding.
Imatinib mesylate (Gleevec) may not be effective at treating ...Dec 21, 2005 News-Medical.net, Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs ...
Dishman to expand EM capacity to 7.2mtJan 12, 2006 Business Standard, Dishman Pharmaceuticals plans to increase installed capacity of its Eprosartan Mesylate (EM) plant from 6. MT to 7.2 MT per month to meet the future demand of ...
Oscient Pharmaceuticals Provides Preliminary Revenues for Fourth ...Jan 9, 2006 Genetic Engineering News, ...quarter revenues of approximately $9.2 million, with approximately $8 million in revenue from its lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, and ...
Bio-IT BriefsJan 12, 2006 Bio-IT World, ...pharmacokinetic profile and potential efficacy of IPI-504 in patients with gastrointestinal stromal tumors (GIST) resistant to Gleevec (imatinib mesylate). ...
Oscient Pharmaceuticals to Present at 24th Annual JPMorgan ...Jan 3, 2006 Genetic Engineering News, CEO, Steven Rauscher, will provide an overview of the Company as well as an update on the market performance of FACTIVE(R) (gemifloxacin mesylate) tablets, the ...
Infinity Initiates Phase I Clinical Trial of IPI-504 for Patients ...Jan 10, 2006 PR Newswire (press release), ...pharmacokinetic profile and potential efficacy of IPI-504 in patients with gastrointestinal stromal tumors (GIST) resistant to Gleevec(R) (imatinib mesylate). ...
Effectiveness of Gleevec® Plus Hydroxyurea for Treatment of ...Dec 22, 2005 Cancer Consultants (press release), ...from the University of Pittsburgh, Dulman, Germany, and Duke University have reported that the combination of Gleevec (imatinib mesylate) plus hydroxyurea ...
Vaccine for Chronic Myeloid Leukemia Active in Patients with ...Jan 5, 2006 Business Wire (press release), ...of positive interim data for a novel vaccine known as VAX100 for patients with persistent chronic myeloid leukemia (CML) while on imatinib mesylate (Gleevec(R ...
New Pharmaceutical Treatment Options in the ElderlyDec 14, 2005 Medscape (subscription) Gemifloxacin mesylate (Factive). Gemifloxacin mesylate, which is given daily (320 mg for 5 to 7 days), is a new fluoroquinolone ...
Drug questionable in some kidney cancersDec 22, 2005 United Press International The drug in question, imatinib mesylate, used to treat patients with gastrointestinal stromal cancers, is said not likely to be effective for patients with high ...
Vaccine Shows Promise Against Residual Chronic Myeloid LeukemiaDec 27, 2005 Cancer Consultants (press release), Use of a cancer vaccine after treatment with Gleevec® (imatinib mesylate) may reduce or eliminate residual leukemia in some patients with chronic myeloid ...
Investigational Drug Shows Promise in Gleevec®-Resistent CMLDec 29, 2005 Cancer Consultants (press release), AMN107 has produced treatment responses in some patients with chronic myeloid leukemia (CML) that does not respond to Gleevec® (imatinib mesylate), as well as ...
Treatment with Gleevec® Continues to Show Benefits in CMLDec 28, 2005 Cancer Consultants (press release), ...to updated study results presented at the 47th annual meeting of the American Society of Hematology (ASH), Gleevec® (imatinib mesylate) produces good long ...
Ramoplanin Demonstrates High Activity Against Wide Array of ...Dec 19, 2005 PharmaLive.com (press release), The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ...
Gleevec® plus Hydroxyurea Beneficial for Some Patients with ...Dec 20, 2005 Cancer Consultants (press release), ...to a recent article published in the Journal of Clinical Oncology, the treatment combination consisting of Gleevec (imatinib mesylate) plus hydroxyurea ...
Desatinib Promising for Patients with CML Who Do Not Respond to ...Dec 23, 2005 Cancer Consultants (press release), ...still in clinical trials, is an effective treatment option for patients with chronic myelogenous leukemia (CML) who do not respond to Gleevec (imatinib mesylate ...
Glivec Seeking to Become First Targeted Treatment for Adult ...Dec 13, 2005 PharmaLive.com (press release), December 13, 2005 – Novartis has submitted a marketing authorization application for Glivec® (imatinib) Known as Gleevec® (imatinib mesylate) tablets in ...
Restless Legs Syndrome Fact SheetDec 14, 2005 Community Dispatch (press release) Dopamine agonists such as pergolide mesylate, pramipexole, and ropinirole hydrochloride may be effective in some patients and are less likely to cause ...
Those restless legs16 Jan 2006 Pittsburgh Tribune-Review, Other dopamine agonists include pergolide, sold as Permax, and pramipexole, sold as Mirapex. Both are used to treat moderate to severe RLS. ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
